173 related articles for article (PubMed ID: 23361053)
1. Regulation of tamoxifen sensitivity by a PAK1-EBP1 signalling pathway in breast cancer.
Ghosh A; Awasthi S; Peterson JR; Hamburger AW
Br J Cancer; 2013 Feb; 108(3):557-63. PubMed ID: 23361053
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of the ErbB3 binding protein Ebp1 by p21-activated kinase 1 in breast cancer cells.
Akinmade D; Talukder AH; Zhang Y; Luo WM; Kumar R; Hamburger AW
Br J Cancer; 2008 Mar; 98(6):1132-40. PubMed ID: 18283314
[TBL] [Abstract][Full Text] [Related]
3. The ErbB3 binding protein EBP1 regulates ErbB2 protein levels and tamoxifen sensitivity in breast cancer cells.
Lu Y; Zhou H; Chen W; Zhang Y; Hamburger AW
Breast Cancer Res Treat; 2011 Feb; 126(1):27-36. PubMed ID: 20379846
[TBL] [Abstract][Full Text] [Related]
4. EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance.
Zhang Y; Linn D; Liu Z; Melamed J; Tavora F; Young CY; Burger AM; Hamburger AW
Mol Cancer Ther; 2008 Oct; 7(10):3176-86. PubMed ID: 18852121
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells.
Gonzalez N; Cardama GA; Comin MJ; Segatori VI; Pifano M; Alonso DF; Gomez DE; Menna PL
Cell Signal; 2017 Jan; 30():154-161. PubMed ID: 27939839
[TBL] [Abstract][Full Text] [Related]
6. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
[TBL] [Abstract][Full Text] [Related]
7. Sliding p21-activated kinase 1 to nucleus impacts tamoxifen sensitivity.
Rayala SK; Kumar R
Biomed Pharmacother; 2007 Aug; 61(7):408-11. PubMed ID: 17604944
[TBL] [Abstract][Full Text] [Related]
8. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.
Arias-Romero LE; Villamar-Cruz O; Pacheco A; Kosoff R; Huang M; Muthuswamy SK; Chernoff J
Oncogene; 2010 Oct; 29(43):5839-49. PubMed ID: 20711231
[TBL] [Abstract][Full Text] [Related]
9. Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
Tan S; Ding K; Chong QY; Zhao J; Liu Y; Shao Y; Zhang Y; Yu Q; Xiong Z; Zhang W; Zhang M; Li G; Li X; Kong X; Ahmad A; Wu Z; Wu Q; Zhao X; Lobie PE; Zhu T
J Biol Chem; 2017 Aug; 292(33):13551-13564. PubMed ID: 28637868
[TBL] [Abstract][Full Text] [Related]
10. The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.
Awasthi S; Ezelle H; Hassel BA; Hamburger AW
Mol Cell Biochem; 2015 Jul; 405(1-2):177-86. PubMed ID: 25876877
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of tyrosine 285 of PAK1 facilitates βPIX/GIT1 binding and adhesion turnover.
Hammer A; Oladimeji P; De Las Casas LE; Diakonova M
FASEB J; 2015 Mar; 29(3):943-59. PubMed ID: 25466889
[TBL] [Abstract][Full Text] [Related]
12. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
13. Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance.
Hirokawa Y; Arnold M; Nakajima H; Zalcberg J; Maruta H
Cancer Biol Ther; 2005 Sep; 4(9):956-60. PubMed ID: 16082189
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells.
Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW
Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049
[TBL] [Abstract][Full Text] [Related]
15. [The role of protein kinase PAK1 in the regulation of estrogen-independent growth of breast cancer].
Avilova EA; Andreeva OE; Shatskaia VA; Krasil'nikov MA
Biomed Khim; 2014; 60(3):322-31. PubMed ID: 25019394
[TBL] [Abstract][Full Text] [Related]
16. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.
Pancholi S; Lykkesfeldt AE; Hilmi C; Banerjee S; Leary A; Drury S; Johnston S; Dowsett M; Martin LA
Endocr Relat Cancer; 2008 Dec; 15(4):985-1002. PubMed ID: 18824559
[TBL] [Abstract][Full Text] [Related]
17. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.
Godinho MF; Wulfkuhle JD; Look MP; Sieuwerts AM; Sleijfer S; Foekens JA; Petricoin EF; Dorssers LC; van Agthoven T
Br J Cancer; 2012 Sep; 107(6):947-55. PubMed ID: 22892392
[TBL] [Abstract][Full Text] [Related]
18. Transfer-RNA-mediated enhancement of ribosomal proteins S6 kinases signaling for cell proliferation.
Kwon NH; Lee MR; Kong J; Park SK; Hwang BJ; Kim BG; Lee ES; Moon HG; Kim S
RNA Biol; 2018; 15(4-5):635-648. PubMed ID: 28816616
[TBL] [Abstract][Full Text] [Related]
19. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
20. [Relation between c-erbB1, c-erbB2, MAPK expression and resistance to tamoxifen in breast cancer cells in vitro].
Zhang QY; Zhao WH; Kang XM
Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):826-30. PubMed ID: 17416003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
